ストックスクリーナーアプリを入手
15.70
2.00%
-0.32
アフターアワーズ：
15.70
前日終値:
$16.02
開ける：
$16.24
24時間の取引高:
772.62K
Relative Volume:
0.58
時価総額：
$1.32B
収益：
-
当期純損益:
$-15.28M
株価収益率:
-31.02
EPS:
-0.5061
ネットキャッシュフロー:
$-32.97M
1週間 パフォーマンス:
+0.51%
1か月 パフォーマンス:
+6.88%
6か月 パフォーマンス:
+108.50%
1年 パフォーマンス:
+340.39%
1日の値動き範囲:
$15.33
$16.30
1週間の範囲:
$14.11
$16.34
52週間の値動き範囲:
$3.165
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
名前
Corvus Pharmaceuticals Inc
セクター
電話
(650) 900-4520
住所
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
15.70 | 1.35B | 0 | -15.28M | -32.97M | -0.5061 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-17 | 開始されました | Goldman | Buy |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-01-02 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-18 | 開始されました | Oppenheimer | Outperform |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-05-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-02-10 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-05-29 | 開始されました | ROTH Capital | Buy |
| 2017-08-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 開始されました | Credit Suisse | Outperform |
| 2016-04-18 | 開始されました | Guggenheim | Buy |
すべてを表示
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board - Sahm
Could Corvus Pharmaceuticals’ (CRVS) New Board Appointment Reframe Its Immunology Strategy And Competitive Edge? - Sahm
MSN Money - MSN
Corvus Pharmaceuticals (CRVS.US) will release its earnings report after the market closes on May 7. - Moomoo
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) to Release Earnings on Thursday - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.3%Here's Why - MarketBeat
CRVS stock surges 10%, hits 50-DMA for first time in a month – here’s why Goldman Sachs sees a 166% upside - MSN
Corvus Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Corvus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Chan Andrew C. - Moomoo
Corvus Pharmaceuticals (CRVS) director granted 30,000 stock options at $16.02 - Stock Titan
Corvus Pharmaceuticals (CRVS) director Andrew Chan files Form 3 - Stock Titan
BlackRock (NYSE: BLK) holds 5.39M shares of Corvus Pharmaceuticals (CRVS) - Stock Titan
Goldman Sachs initiates coverage of Corvus Pharmaceuticals (CRVS) with buy recommendation - MSN
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Corvus jumps as Goldman Sachs initiates at buy on lead asset - MSN
Corvus Pharma stock dips over 6% after-hours following best day ever — what went wrong? - MSN
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Is Corvus Pharmaceuticals (CRVS) Reframing Its Immunology Strategy With Soquelitinib’s Drug‑Free Remission Narrative? - Sahm
Corvus Pharmaceuticals (NASDAQ: CRVS) outlines 2026 virtual meeting and pay vote - Stock Titan
Corvus Pharmaceuticals appoints ex-Genentech executive to board By Investing.com - Investing.com India
Corvus Pharmaceuticals Announces Board Changes and New Director - TipRanks
New Corvus (NASDAQ: CRVS) director joins as Scott Morrison exits - Stock Titan
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2%Here's Why - MarketBeat
Corvus Pharmaceuticals appoints ex-Genentech executive to board - Investing.com
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - marketscreener.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 9.5%What's Next? - MarketBeat
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting - The Manila Times
Corvus spotlights eczema drug data, including late-breaker remission results - Stock Titan
Corvus (CRVS) Stock: Build a Position? (Smart Money Exits) 2026-04-20Social Momentum Signals - Cổng thông tin điện tử Tỉnh Sơn La
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group - MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings - Sahm
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat
Corvus jumps as Goldman Sachs initiates at Buy on lead asset - Seeking Alpha
Goldman Sachs Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $40 - 富途牛牛
Goldman Sachs initiates Corvus Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
Corvus (CRVS) Stock Consolidates (On the Radar) 2026-04-15Micro Trends - UBND thành phố Hải Phòng
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 4.3%Should You Sell? - MarketBeat
CRVS Technical Analysis | Trend, Signals & Chart Patterns | CORVUS PHARMACEUTICALS INC (NASDAQ:CRVS) - ChartMill
Price Action: Is Corvus Pharmaceuticals Inc undervalued by DCF analysis2026 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Corvus Pharmaceuticals Inc (CRVS) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):